Has Theodore Amgott received payments from drug or device companies?

Yes. Drug and device makers reported $2,800 in general payments to Theodore Amgott across 180 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Theodore Amgott did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Theodore Amgott come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Theodore Amgott

Pulmonary Disease · Melbourne, FLNPI 1861485518

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.4% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 26.7% of the total. Reporting peaked in 2019 at $1,014 and has fallen 55.5% since, to $451 in 2022. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.

$2,800in general payments, 2019–2025

Across 180 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$747
Boehringer Ingelheim$597
GSK$539
Grifols USA, LLC$253
Genentech USA, Inc.$121
Merck$79
plus $464 from 16 others

What the payments were for

Food & beverage$2,64394%
Education$1576%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	48	$747
Boehringer Ingelheim	38	$597
GSK	43	$539
Grifols USA, LLC	13	$253
Genentech USA, Inc.	4	$121
Merck	5	$79
Electromed, Inc.	5	$55
Advanced Respiratory, Inc	2	$45
Teva Pharmaceuticals USA, Inc.	3	$45
Actelion Pharmaceuticals US, Inc.	2	$38
Jazz Pharmaceuticals Inc.	2	$33
Philips North America LLC	2	$33
Sunovion Pharmaceuticals Inc.	2	$31
Sanofi	2	$31
Novartis	2	$27
Regeneron Healthcare Solutions, Inc.	1	$24
United Therapeutics Corporation	1	$21
Shire North American Group Inc	1	$19
Amgen	1	$17
CSL Behring	1	$17
Circassia Inc.	1	$16
Mylan Specialty L.p.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Prolastin-C$125

How this compares

$2,800 in reported general payments places this provider in the 45th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida →

Other pulmonary disease in Melbourne

Simmy PintoMelbourne$193K
Franck RahaghiWeston$1.2M
Michael OttEglin Afb$909K
Ali JiwaniOrlando$859K
Anas HadehWeston$800K
Jennifer FultonJacksonville$665K
Ricardo Restrepo-JaramilloTampa$555K
Mark RumbakTampa$528K
Jose Soto SotoJacksonville$504K
Javier Perez FernandezMiami$496K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →